Modulation of Potassium Channels by Antiarrhythmic and Antihypertensive Drugs
Overview
Authors
Affiliations
Agents that modulate cardiac and smooth muscle K+ channels have stimulated considerable interest in recent years because of their therapeutic potential in a number of cardiovascular diseases. Foremost among these drugs are the so-called Class III antiarrhythmic agents, which act by prolonging cardiac action potentials, and K+ channel openers, which hyperpolarize and thereby relax smooth muscle cells. Many of the newly developed Class III antiarrhythmic agents probably act by specific block of one subtype of delayed rectifier K+ current, IKr, whereas other agents block more than one type of cardiac K+ current. Much controversy exists over the specific type of K+ channel (or channels) in smooth muscle that are activated by the K+ channel openers. Both groups of K+ channel modulators have great therapeutic promise, but the Class III antiarrhythmic agents may suffer from a side-effect that is directly linked to their specific mechanism of action.
Forny C, Sube R, Ertel E J Vis Exp. 2018; (140).
PMID: 30394391 PMC: 6235566. DOI: 10.3791/58290.
Daily N, Santos R, Vecchi J, Kemanli P, Wakatsuki T J Evol Stem Cell Res. 2017; 1(2):1-11.
PMID: 28966998 PMC: 5621642. DOI: 10.14302/issn.2574-4372.jesr-16-1395.
Second-generation antihistamines: actions and efficacy in the management of allergic disorders.
Golightly L, Greos L Drugs. 2005; 65(3):341-84.
PMID: 15669879 DOI: 10.2165/00003495-200565030-00004.
A benefit-risk assessment of class III antiarrhythmic agents.
Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Kober L Drug Saf. 2002; 25(12):847-65.
PMID: 12241126 DOI: 10.2165/00002018-200225120-00003.
Emmi A, Wenzel H, Schwartzkroin P, Taglialatela M, Castaldo P, Bianchi L J Neurosci. 2000; 20(10):3915-25.
PMID: 10804231 PMC: 4093789.